Products
Canakinumab Biosimilar Monoclonal Antibody (IL-1β) for Research
Pre-Made Canakinumab biosimilar, Whole mAb, Anti-IL1B Antibody: Anti-IL-1/IL1-BETA/IL1F2/IL1beta therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Canakinumab (INN), sold under the brand name Ilaris is a medication for the treatment of systemic juvenile idiopathic arthritis (SJIA) and active Still's disease, including adult-onset Still's disease (AOSD). It is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-091-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Canakinumab biosimilar, Whole mAb, Anti-IL1B Antibody: Anti-IL-1/IL1-BETA/IL1F2/IL1beta therapeutic antibody |
| INN Name | Canakinumab |
| Target | IL1B |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | 4g5z:HL/5bvj:HG:FE:BA:DC/4g6j:HL/5bvp:HL |
| 95-98% SI Structure | None |
| Year Proposed | 2007 |
| Year Recommended | 2008 |
| Companies | Charite - Universitatsmedizin Berlin;Novartis;Triemli hospital;University Hospital Tubingen;University Hospital Zurich |
| Conditions Approved | Adult-onset Still's disease;Cryopyrin-associated periodic syndromes;Familial autosomal dominant periodic fever;Familial Mediterranean fever;Gouty arthritis;Juvenile rheumatoid arthritis;Peroxisomal disorders |
| Conditions Active | Cardiovascular disorders;Behcet's syndrome;Non-small cell lung cancer;Abdominal aortic aneurysm;Atherosclerosis;Malignant melanoma;Osteoarthritis;Peripheral arterial occlusive disorders;Pulmonary sarcoidosis;Schnitzler syndrome;Sickle cell anaemia;Breast cancer;Pancreatic cancer;Renal cell carcinoma |
| Conditions Discontinued | Chronic obstructive pulmonary disease;Asthma;Diabetic retinopathy;Polymyalgia rheumatica;Rheumatoid arthritis;Type 1 diabetes mellitus;Type 2 diabetes mellitus |
| Development Tech | Medarex UltiMAb Mouse |
About target - IL1B
1. Protein Interleukin-1 beta
2. Gene IL1B
3. Organism Homo sapiens (Human)
Function
Potent proinflammatory cytokine. Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production. Promotes Th17 differentiation of T-cells. Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells (PubMed:10653850).
Plays a role in angiogenesis by inducing VEGF production synergistically with TNF and IL6 (PubMed:12794819).
Miscellaneous
The IL1B production occurs in 2 steps, each being controlled by different stimuli. First, inflammatory signals, such as LPS, stimulate the synthesis and promote the accumulation of cytosolic stores of pro-IL1B (priming). Then additional signals are required for inflammasome assembly, leading to CASP1 activation, pro-IL1B processing and eventually secretion of the active cytokine. IL1B processing and secretion are temporarily associated.
